Drugs / BNT411
last change May 2024 re-read 2 minutes ago

BNT411

targets TLR7 via activation

Developed for
small cell lung carcinoma
Investigated by
BioNTech SE

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04101357 Jun 2020 → Jan 2024 small cell lung carcinoma BioNTech SE Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BNT411 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04101357
Action Activate “BNT411 is a toll-like receptor 7 (TLR7) agonist” NCT04101357
Target TLR7 “BNT411 is a toll-like receptor 7 (TLR7) agonist” NCT04101357